Viret Jean-Frederic 4
4 · Coherus BioSciences, Inc. · Filed Feb 21, 2020
Insider Transaction Report
Form 4
Viret Jean-Frederic
Chief Financial Officer
Transactions
- Sale
Common Stock, $0.0001 par value
2020-02-19$22.33/sh−3,159$70,552→ 46,841 total - Exercise/Conversion
Common Stock, $0.0001 par value
2020-02-19$10.05/sh+3,159$31,748→ 50,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2020-02-19−3,159→ 101,569 totalExercise: $10.05Exp: 2028-02-01→ Common Stock (3,159 underlying)
Footnotes (4)
- [F1]Includes 31,250 restricted stock units.
- [F2]The sales reported in this Form 4 were effected pursuant to one or more Rule 10b5-1 trading plans adopted by Reporting Person.
- [F3]The transaction was executed in multiple trades in prices ranging from $22.09 to $22.73, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the Issuer, or a stockholder of the Issuer, information regarding the number of shares and prices at which the transaction was effected.
- [F4]The underlying shares subject to the option vest and become exercisable as to 1/48th of the total number of shares subject to the option in successive, equal monthly installments measured from February 1, 2018, subject to Reporting Person's continued service relationship with the Issuer on each such vesting date.